News & Updates

The benefit of anakinra treatment in patients hospitalized with COVID-19 is consistent regardless of age, sex, comorbidities, and suPAR* levels, according to subgroup analysis of the SAVE-MORE trial.

Inpatient rehabilitation with a comprehensive rehabilitation program offers benefits to post-COVID-19 patients, reports a Singapore study, noting that functional outcomes may be further improved with adjunct robotic therapy.

In women who have contracted COVID-19, the presence of polycystic ovary syndrome (PCOS) does not appear to drive the risk of increased disease severity, according to a study.

Individuals who have been hospitalized with infection appear to be at higher risk of dementia compared with their peers who are unexposed to infections, as reported in a study.

Treatment with fluvoxamine does not appear to improve outcomes in patients with mild-to-moderate COVID-19, with a study showing that the drug does not shorten symptom duration as compared with placebo.

The neutralizing antibody regdanvimab appears to be useful in the treatment of mild-to-moderate COVID-19, with a recent study showing that the drug may prevent disease worsening in patients, including those infected with the Delta variant.